Michael Narachi - Net Worth and Insider Trading

Michael Narachi Net Worth

The estimated net worth of Michael Narachi is at least $103,156 dollars as of 2024-11-10. Michael Narachi is the Director of AMAG Pharmaceuticals Inc and owns about 7,500 shares of AMAG Pharmaceuticals Inc (AMAG) stock worth over $103,125. Michael Narachi is also the President and CEO of Orexigen Therapeutics Inc and owns about 5,803 shares of Orexigen Therapeutics Inc (OREXQ) stock worth over $31. Details can be seen in Michael Narachi's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Michael Narachi has not made any transactions after 2014-09-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Michael Narachi

To

Michael Narachi Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael Narachi owns 4 companies in total, including Ultragenyx Pharmaceutical Inc (RARE) , Orexigen Therapeutics Inc (OREXQ) , and Eiger BioPharmaceuticals Inc (EIGRQ) among others .

Click here to see the complete history of Michael Narachi’s form 4 insider trades.

Insider Ownership Summary of Michael Narachi

Ticker Comapny Transaction Date Type of Owner
RARE Ultragenyx Pharmaceutical Inc 2015-02-20 director
OREXQ Orexigen Therapeutics Inc 2017-10-13 director & CEO & President
EIGRQ Eiger BioPharmaceuticals Inc 2014-01-29 director
LIMIT LIMIT 2013-05-23 director

Michael Narachi Latest Holdings Summary

Michael Narachi currently owns a total of 2 stocks. Among these stocks, Michael Narachi owns 7,500 shares of AMAG Pharmaceuticals Inc (AMAG) as of May 25, 2012, with a value of $103,125 and a weighting of 99.97%. Michael Narachi also owns 5,803 shares of Orexigen Therapeutics Inc (OREXQ) as of September 15, 2014, with a value of $31 and a weighting of 0.03%.

Latest Holdings of Michael Narachi

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AMAG AMAG Pharmaceuticals Inc 2012-05-25 7,500 13.75 103,125
OREXQ Orexigen Therapeutics Inc 2014-09-15 5,803 0.01 31

Holding Weightings of Michael Narachi


Michael Narachi Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael Narachi has made a total of 0 transactions in AMAG Pharmaceuticals Inc (AMAG) over the past 5 years. The most-recent trade in AMAG Pharmaceuticals Inc is the acquisition of 7,500 shares on May 25, 2012, which cost Michael Narachi around $27,075.

According to the SEC Form 4 filings, Michael Narachi has made a total of 0 transactions in Orexigen Therapeutics Inc (OREXQ) over the past 5 years. The most-recent trade in Orexigen Therapeutics Inc is the acquisition of 5,000 shares on September 15, 2014, which cost Michael Narachi around $239,000.

Insider Trading History of Michael Narachi

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael Narachi Trading Performance

GuruFocus tracks the stock performance after each of Michael Narachi's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael Narachi is 15.29%. GuruFocus also compares Michael Narachi's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael Narachi within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Michael Narachi's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Michael Narachi

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -5.66 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -2.44 LIMIT LIMIT LIMIT LIMIT LIMIT

Michael Narachi Ownership Network

Ownership Network List of Michael Narachi

No Data

Ownership Network Relation of Michael Narachi

Insider Network Chart

Michael Narachi Owned Company Details

What does Ultragenyx Pharmaceutical Inc do?

Who are the key executives at Ultragenyx Pharmaceutical Inc?

Michael Narachi is the director of Ultragenyx Pharmaceutical Inc. Other key executives at Ultragenyx Pharmaceutical Inc include Chief Financial Officer Howard Horn , director & 10 percent owner & President & CEO Emil D Kakkis , and Controller and PAO Theodore Alan Huizenga .

Ultragenyx Pharmaceutical Inc (RARE) Insider Trades Summary

Over the past 18 months, Michael Narachi made no insider transaction in Ultragenyx Pharmaceutical Inc (RARE). Other recent insider transactions involving Ultragenyx Pharmaceutical Inc (RARE) include a net sale of 147,853 shares made by Emil D Kakkis , a net sale of 4,391 shares made by Sanders Corazon (corsee) D. , and a net sale of 3,565 shares made by Theodore Alan Huizenga .

In summary, during the past 3 months, insiders sold 27,556 shares of Ultragenyx Pharmaceutical Inc (RARE) in total and bought 0 shares, with a net sale of 27,556 shares. During the past 18 months, 260,421 shares of Ultragenyx Pharmaceutical Inc (RARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 260,421 shares.

Ultragenyx Pharmaceutical Inc (RARE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Ultragenyx Pharmaceutical Inc Insider Transactions

No Available Data

Michael Narachi Mailing Address

Above is the net worth, insider trading, and ownership report for Michael Narachi. You might contact Michael Narachi via mailing address: C/o Orexigen Therapeutics, Inc., 3344 N Torrey Pines Ct, #200, La Jolla Ca 92037.